Does Dr. MAYSA ABU-KHALAF have financial conflicts of interest?

Dr. MAYSA ABU-KHALAF (MD) has received a total of $8,561 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $2,487 in personal promotional payouts (consulting, meals, travel) and $6,073 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MAYSA ABU-KHALAF?

According to CMS Open Payments data, Dr. MAYSA ABU-KHALAF received funding from ELI LILLY AND COMPANY ($6,113), PFIZER ($1,890), and NOVARTIS PHARMACEUTICALS CORPORATION ($173).

Does Dr. MAYSA ABU-KHALAF receive research grants or speaking fees?

Dr. MAYSA ABU-KHALAF has received $2,487 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $6,073 in clinical research grants.

DR. MAYSA ABU-KHALAF

MDReal-Time Hydrated

Specialty: Internal Medicine, Medical Oncology

Practice Location: PHILADELPHIA, PA 19107

NPI Number: 1194713495

LIFETIME INDUSTRY VALUE

$8,561

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABU-KHALAF is a verified Internal Medicine, Medical Oncology practitioner based in PHILADELPHIA, PA.

Between 2021 and 2024, Dr. ABU-KHALAF had an overall industry promotional and research financial footprint of $8,561 as recorded in the federal CMS Open Payments database.

$2,487 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$6,073 was allocated to sponsored clinical trials and medical research activities.

Dr. ABU-KHALAF's primary funding source is ELI LILLY AND COMPANY, which accounts for $6,113 (representing 71.4% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ELI LILLY AND COMPANY

Rank 1

$6,113

71.4%

PFIZER

Rank 2

$1,890

22.1%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 3

$173

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.